Antiviral agents position statement, Royal College of Physicians

Key messages Remdesivir (NHS stock) is in limited supply and should only be offered to patients who meet all the ' eligibility criteria ' and ' additional criteria ' as outlined in the UK 2 External 0 0 0interim Clinical Commissioning Policy false https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAttachment.aspx?Attachment_id=103672 true false%> for remdesvir Co-administration of dexmathasone or hydrocortisone is recommended for patients with critical or severe COVID-19, or those requiring supplemental oxygen to maintain target saturation – see 2 External 0 0 0CTAG treatment pathway false https://www.ctag-support.org.uk/wp-content/uploads/2020/07/CTAG-flow-diagram.pdf true false%> Hospitals managing COVID-19 cases should make every effort to enrol COVID-19 patients in national priority clinical trials Suspected side effects to medicines used in coronavirus treatment should be reported via the Yellow Card COVID-19 reporting site: 2 External 0 0 0https://coronavirus-yellowcard.mhra.gov.uk/ false https://coronavirus-yellowcard.mhra.gov.uk/ true false%>
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news